The Latest Breaking News from PFE

These dividend stocks have consistently paid dividends with yields over 6%.

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…